EUVIMEDEUVIMED entdecken
Crossref

Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

Katina Zheng iD, Amirhossein Azhie, Xiaoting You, Maryam Naghibzadeh, Eunice Tan, Sara Naimimohasses, Vikas S Sridhar iD, Sarang Gupta, Shiyi Chen, Satya Dash, Cynthia Tsien, Nazia Selzner und 6 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Katina Zheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Liver Transplantation, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the Toronto General and Western Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in liver transplant (LT) recipients with diabetes.

Methods

A single‐centre, retrospective analysis of prospectively collected data from an LT recipient database (1990–2023) was conducted. We included adults with pre‐existing diabetes and post‐transplant diabetes, newly started on GLP‐1RAs and/or SGLT2 inhibitors after LT. Metabolic and biochemical parameters and outcomes were collected for up to 12 months after starting medications and were compared to those in patients receiving dipeptidyl peptidase‐4 (DPP‐4) inhibitors. Statistical analysis included descriptive statistics and linear mixed models.

Results

We included participants on GLP‐1RAs ( n = 46), SGLT2 inhibitors ( n = 87), combination therapy ( n = 12), and a DPP‐4 inhibitor comparator ( n = 217). Both GLP‐1RAs and combination therapy decreased mean glycated haemoglobin (HbA1c) levels, and combination therapy remained significant when adjusted for DPP‐4 inhibitor treatment (−3.5%, 95% CI [−6.1, −0.95]; p = 0.0089) at 12 months. All three groups had significant decreases in mean weight and body mass index, but these remained significant in the GLP‐1RA (−5.2 kg, 95% CI [−8.7, −1.7], p = 0.0039 and 1.99 kg/m 2 , 95% CI [−3.4, −0.6], p = 0.0048) and combination therapy groups (−5.4 kg, 95% CI [−10.5, −0.36], p = 0.04 and −3.4 kg/m 2 , 95% CI [−5.5, −1.3], p = 0.0015) when adjusted for DPP‐4 inhibitor treatment at 12 months. Alanine aminotransferase levels decreased with GLP‐1RA and combination therapy. There were two (1.4%) cases of graft rejection.

Conclusion

We found that GLP‐1RAs, SGLT2 inhibitors, and their combination, led to significant weight loss in LT recipients with diabetes. Combination therapy, in particular, lowered HbA1c and alanine aminotransferase levels compared to DPP‐4 inhibitors. Further studies are needed to assess long‐term safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsLiver TransplantationDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedGlycated HemoglobinDrug Therapy, CombinationAdultTreatment OutcomeBlood Glucose

Stichwörter der Autor:innen

DPP‐4 inhibitorsGLP‐1 receptor agonistsSGLT2 inhibitorsdiabetes mellitusliver transplantation

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, humanBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Multi Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
  • Division of Endocrinology and Metabolism, University Health Network, Toronto, Ontario, Canada.
  • Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.
  • Division of Gastroenterology and Hepatology, University Health Network, Toronto, Ontario, Canada.

ORCID-Profile: Katina Zheng, Vikas S Sridhar, Mamatha Bhat

Förderung

  • the Toronto General and Western Hospital Foundation

Zitieren

APA

Zheng, K., Azhie, A., You, X., Naghibzadeh, M., Tan, E., Naimimohasses, S., Sridhar, V. S., Gupta, S., Chen, S., Dash, S., Tsien, C., Selzner, N., Lilly, L., Jaeckel, E., Woo, M., Singh, S., Cherney, D., & Bhat, M. (2024). Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15769

Vancouver

Zheng K, Azhie A, You X, Naghibzadeh M, Tan E, Naimimohasses S, et al. Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15769

BibTeX
@article{Zheng2024,
  author = {Zheng, Katina and Azhie, Amirhossein and You, Xiaoting and Naghibzadeh, Maryam and Tan, Eunice and Naimimohasses, Sara and Sridhar, Vikas S and Gupta, Sarang and Chen, Shiyi and Dash, Satya and Tsien, Cynthia and Selzner, Nazia and Lilly, Leslie and Jaeckel, Elmar and Woo, Minna and Singh, Sunita and Cherney, David and Bhat, Mamatha},
  title = {Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15769}
}
Kostenlos starten →